Published in Nanomedicine on May 15, 2009
Selective capture of cesium and thallium from natural waters and simulated wastes with copper ferrocyanide functionalized mesoporous silica. J Hazard Mater (2010) 0.97
Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging. Clin J Am Soc Nephrol (2010) 0.93
Functionalized nanoporous silica for the removal of heavy metals from biological systems: adsorption and application. ACS Appl Mater Interfaces (2010) 0.86
Silica microparticles as a solid support for gadolinium phosphonate magnetic resonance imaging contrast agents. J Am Chem Soc (2012) 0.85
Basic MR relaxation mechanisms and contrast agent design. J Magn Reson Imaging (2015) 0.83
Improving T₁ and T₂ magnetic resonance imaging contrast agents through the conjugation of an esteramide dendrimer to high-water-coordination Gd(III) hydroxypyridinone complexes. Contrast Media Mol Imaging (2012) 0.81
Functional sorbents for selective capture of plutonium, americium, uranium, and thorium in blood. Health Phys (2010) 0.79
Novel oral detoxification of mercury, cadmium, and lead with thiol-modified nanoporous silica. ACS Appl Mater Interfaces (2014) 0.77
Analysis of Lanthanide Complex Dendrimer Conjugates for Bimodal NIR and MRI Imaging. Macromolecules (2012) 0.76
Nanoporous sorbent material as an oral phosphate binder and for aqueous phosphate, chromate, and arsenate removal. J Nanomed Nanotechnol (2014) 0.75
Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant (2006) 7.13
Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol (2007) 3.26
Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol (2006) 3.25
Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet (2000) 2.66
Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology (2008) 2.16
Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol (1998) 2.13
Rational design of sequestering agents for plutonium and other actinides. Chem Rev (2003) 1.92
Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol (2006) 1.81
What nephrologists need to know about gadolinium. Nat Clin Pract Nephrol (2007) 1.60
Actinide sequestration using self-assembled monolayers on mesoporous supports. Environ Sci Technol (2005) 1.48
Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant (2007) 1.41
Incorporation of hydroxypyridinone ligands into self-assembled monolayers on mesoporous supports for selective actinide sequestration. Environ Sci Technol (2005) 1.18
Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol (2006) 1.17
Severe hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenine-induced uraemia. Nephrol Dial Transplant (2005) 1.16
Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant (2007) 1.14
Hydroxypyridinone functionalized self-assembled monolayers on nanoporous silica for sequestering lanthanide cations. J Nanosci Nanotechnol (2005) 1.07
Safety of gadolinium contrast agent in hemodialysis patients. Acta Radiol (2001) 0.96
Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Cancer Imaging (2007) 0.94
Dialyzability of gadodiamide in hemodialysis patients. Radiat Med (2006) 0.88
Influence of hemoperfusion on the concentration of beta-methyldigoxin and hormones in plasma. Kidney Int (1979) 0.84
Using highly concentrated gadobutrol as an MR contrast agent in patients also requiring hemodialysis: safety and dialysability. AJR Am J Roentgenol (2002) 0.80
The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell (2002) 6.81
Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science (2006) 6.55
The pathogen-associated iroA gene cluster mediates bacterial evasion of lipocalin 2. Proc Natl Acad Sci U S A (2006) 2.63
Selective molecular recognition, C-H bond activation, and catalysis in nanoscale reaction vessels. Acc Chem Res (2005) 2.24
"Cymothoe sangaris": an extremely stable and highly luminescent 1,2-hydroxypyridinonate chelate of Eu(III). J Am Chem Soc (2006) 2.21
Brilliant Sm, Eu, Tb, and Dy chiral lanthanide complexes with strong circularly polarized luminescence. J Am Chem Soc (2007) 2.14
Iron traffics in circulation bound to a siderocalin (Ngal)-catechol complex. Nat Chem Biol (2010) 2.06
Rational design of sequestering agents for plutonium and other actinides. Chem Rev (2003) 1.92
Stable lanthanide luminescence agents highly emissive in aqueous solution: multidentate 2-hydroxyisophthalamide complexes of Sm(3+), Eu(3+), Tb(3+), Dy(3+). J Am Chem Soc (2003) 1.91
Anthrax pathogen evades the mammalian immune system through stealth siderophore production. Proc Natl Acad Sci U S A (2006) 1.81
From antenna to assay: lessons learned in lanthanide luminescence. Acc Chem Res (2009) 1.79
A bifunctional poly(ethylene glycol) silane immobilized on metallic oxide-based nanoparticles for conjugation with cell targeting agents. J Am Chem Soc (2004) 1.73
Toward optimized high-relaxivity MRI agents: the effect of ligand basicity on the thermodynamic stability of hexadentate hydroxypyridonate/catecholate gadolinium(III) complexes. Inorg Chem (2003) 1.69
Gadolinium(III) 1,2-hydroxypyridonate-based complexes: toward MRI contrast agents of high relaxivity. Inorg Chem (2004) 1.68
High relaxivity gadolinium hydroxypyridonate-viral capsid conjugates: nanosized MRI contrast agents. J Am Chem Soc (2008) 1.66
Acid catalysis in basic solution: a supramolecular host promotes orthoformate hydrolysis. Science (2007) 1.63
High-relaxivity MRI contrast agents: where coordination chemistry meets medical imaging. Angew Chem Int Ed Engl (2008) 1.61
Enantiopure, octadentate ligands as sensitizers for europium and terbium circularly polarized luminescence in aqueous solution. J Am Chem Soc (2007) 1.60
The permeability transition pore controls cardiac mitochondrial maturation and myocyte differentiation. Dev Cell (2011) 1.52
Magnetic resonance contrast agents from viral capsid shells: a comparison of exterior and interior cargo strategies. Nano Lett (2007) 1.51
Substituent effects on Gd(III)-based MRI contrast agents: optimizing the stability and selectivity of the complex and the number of coordinated water molecules. Inorg Chem (2006) 1.49
Highly luminescent lanthanide complexes of 1-hydroxy-2-pyridinones. Inorg Chem (2008) 1.43
Removal of heavy metals from aqueous systems with thiol functionalized superparamagnetic nanoparticles. Environ Sci Technol (2007) 1.39
Hexadentate hydroxypyridonate iron chelators based on TREN-Me-3,2-HOPO: variation of cap size. Inorg Chem (2002) 1.38
Gd-hydroxypyridinone (HOPO)-based high-relaxivity magnetic resonance imaging (MRI) contrast agents. Acc Chem Res (2009) 1.35
Siderophores of Bacillus anthracis, Bacillus cereus, and Bacillus thuringiensis. Biochem Biophys Res Commun (2006) 1.33
Highly soluble tris-hydroxypyridonate Gd(III) complexes with increased hydration number, fast water exchange, slow electronic relaxation, and high relaxivity. J Am Chem Soc (2007) 1.32
Mitochondria as a drug target in ischemic heart disease and cardiomyopathy. Circ Res (2012) 1.31
An octadentate luminescent Eu(III) 1,2-HOPO chelate with potent aqueous stability. Inorg Chem (2007) 1.28
1,2-hydroxypyridonates as contrast agents for magnetic resonance imaging: TREN-1,2-HOPO. Inorg Chem (2007) 1.27
Proton-mediated chemistry and catalysis in a self-assembled supramolecular host. Acc Chem Res (2009) 1.26
Tuning the coordination number of hydroxypyridonate-based gadolinium complexes: implications for MRI contrast agents. J Am Chem Soc (2006) 1.25
Bacillibactin-mediated iron transport in Bacillus subtilis. J Am Chem Soc (2006) 1.22
Petrobactin-mediated iron transport in pathogenic bacteria: coordination chemistry of an unusual 3,4-catecholate/citrate siderophore. J Am Chem Soc (2008) 1.20
Dendrimeric gadolinium chelate with fast water exchange and high relaxivity at high magnetic field strength. J Am Chem Soc (2005) 1.20
Multivalent, high-relaxivity MRI contrast agents using rigid cysteine-reactive gadolinium complexes. J Am Chem Soc (2011) 1.20
Electrochemical sensors for the detection of lead and other toxic heavy metals: the next generation of personal exposure biomonitors. Environ Health Perspect (2007) 1.19
The siderocalin/enterobactin interaction: a link between mammalian immunity and bacterial iron transport. J Am Chem Soc (2008) 1.19
Predicting efficient antenna ligands for Tb(III) emission. Inorg Chem (2009) 1.18
Incorporation of hydroxypyridinone ligands into self-assembled monolayers on mesoporous supports for selective actinide sequestration. Environ Sci Technol (2005) 1.18
Biomimetic actinide chelators: an update on the preclinical development of the orally active hydroxypyridonate decorporation agents 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO). Health Phys (2010) 1.17
Water-soluble 2-hydroxyisophthalamides for sensitization of lanthanide luminescence. Inorg Chem (2008) 1.17
Molecular recognition and stabilization of iminium ions in water. J Am Chem Soc (2006) 1.14
Siderophore-mediated iron acquisition systems in Bacillus cereus: Identification of receptors for anthrax virulence-associated petrobactin . Biochemistry (2009) 1.12
Conjugation effects of various linkers on Gd(III) MRI contrast agents with dendrimers: optimizing the hydroxypyridinonate (HOPO) ligands with nontoxic, degradable esteramide (EA) dendrimers for high relaxivity. J Am Chem Soc (2011) 1.11
Corynebactin and enterobactin: related siderophores of opposite chirality. J Am Chem Soc (2002) 1.09
Enterobactin protonation and iron release: structural characterization of the salicylate coordination shift in ferric enterobactin. J Am Chem Soc (2006) 1.09
Aryl-bridged 1-hydroxypyridin-2-one: sensitizer ligands for Eu(III). Inorg Chem (2008) 1.08
Microbial evasion of the immune system: structural modifications of enterobactin impair siderocalin recognition. J Am Chem Soc (2006) 1.08
Hydroxypyridinone functionalized self-assembled monolayers on nanoporous silica for sequestering lanthanide cations. J Nanosci Nanotechnol (2005) 1.07
The role of electrostatics in siderophore recognition by the immunoprotein Siderocalin. J Am Chem Soc (2008) 1.06
A highly stable gadolinium complex with a fast, associative mechanism of water exchange. J Am Chem Soc (2003) 1.05
Supramolecular catalysis of a unimolecular transformation: aza-Cope rearrangement within a self-assembled host. Angew Chem Int Ed Engl (2004) 1.04
Aza Cope rearrangement of propargyl enammonium cations catalyzed by a self-assembled "nanozyme". J Am Chem Soc (2008) 1.03
Siderophore-mediated iron transport in Bacillus subtilis and Corynebacterium glutamicum. J Biol Inorg Chem (2006) 1.03
Characterization of a Bacillus subtilis transporter for petrobactin, an anthrax stealth siderophore. Proc Natl Acad Sci U S A (2009) 1.01
Enthalpy-entropy compensation reveals solvent reorganization as a driving force for supramolecular encapsulation in water. J Am Chem Soc (2008) 1.01
Temporal production of the two Bacillus anthracis siderophores, petrobactin and bacillibactin. Biometals (2009) 1.00
A supramolecular approach to combining enzymatic and transition metal catalysis. Nat Chem (2013) 1.00
In vivo evaluation of gadolinium hydroxypyridonate chelates: initial experience as contrast media in magnetic resonance imaging. J Med Chem (2005) 0.99
Equilibrium isotope effects on noncovalent interactions in a supramolecular host-guest system. J Am Chem Soc (2012) 0.98
Molecular recognition and self-assembly special feature: Encapsulation and characterization of proton-bound amine homodimers in a water-soluble, self-assembled supramolecular host. Proc Natl Acad Sci U S A (2009) 0.98
Fe L-edge X-ray absorption spectroscopy determination of differential orbital covalency of siderophore model compounds: electronic structure contributions to high stability constants. J Am Chem Soc (2010) 0.98
Enantioselective catalysis of the aza-Cope rearrangement by a chiral supramolecular assembly. J Am Chem Soc (2009) 0.97
Octadentate cages of Tb(III) 2-hydroxyisophthalamides: a new standard for luminescent lanthanide labels. J Am Chem Soc (2011) 0.97
Selective capture of cesium and thallium from natural waters and simulated wastes with copper ferrocyanide functionalized mesoporous silica. J Hazard Mater (2010) 0.97
Enzymelike catalysis of the Nazarov cyclization by supramolecular encapsulation. J Am Chem Soc (2010) 0.97
Selective removal of lanthanides from natural waters, acidic streams and dialysate. J Hazard Mater (2009) 0.97
Using the antenna effect as a spectroscopic tool: photophysics and solution thermodynamics of the model luminescent hydroxypyridonate complex [Eu(III)(3,4,3-LI(1,2-HOPO))]-. Inorg Chem (2009) 0.96
Optimized relaxivity and stability of [Gd(H(2,2)-1,2-HOPO)(H2O)]- for use as an MRI contrast agent. Inorg Chem (2007) 0.96
Hetero-tripodal hydroxypyridonate gadolinium complexes: syntheses, relaxometric properties, water exchange dynamics, and human serum albumin binding. Inorg Chem (2004) 0.96
Large cooperativity in the removal of iron from transferrin at physiological temperature and chloride ion concentration. J Biol Inorg Chem (2004) 0.95
Voltammetric detection of lead(II) and mercury(II) using a carbon paste electrode modified with thiol self-assembled monolayer on mesoporous silica (SAMMS). Analyst (2003) 0.95
Reversible guest exchange mechanisms in supramolecular host-guest assemblies. Chem Soc Rev (2006) 0.95
The lanthanide contraction revisited. J Am Chem Soc (2007) 0.95